Sagent Pharmaceuticals Issues Nationwide Recall
The company is voluntarily recalling one lot of Oxacillin for Injection, USP, 10 g.
On August 18, 2016, Sagent Pharmaceuticals voluntarily recalled one lot of Oxacillin for Injection, USP, 10 g nationwide due to particulate matter. The recall was in response to a complaint about a single vial containing small, dark particulate matter. The particulate was found in the solution after reconstitution and has been identified iron oxide. Sagent has not received notice of any adverse events associated with the lot.
The recalled product was manufactured by Astral SteriTech Private Limited and distributed by Sagent nationwide from June–July 2016. The product is packaged in cartons containing 10 x 10 gram Pharmacy Bulk Package bottles identified by NDC 25021-163-99. The lot number being recalled is Lot OXT512 (Exp. Date March 2017).
According to Sagent, Oxacillin for Injection, USP, 10 g is available by prescription only for the treatment of infections caused by penicillinase producing staphylococci that have demonstrated susceptibility to the drug. A metal particulate in an injectable product may result in local swelling, irritation of blood vessels or tissue, or blockage of blood vessels.
Sagent is advising customers to quarantine and discontinue distribution of the product. Adverse events may be reported to FDA.
Source: FDA
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
